123 results
Page 2 of 7
F-3
e87bmbn
20 Dec 22
Shelf registration (foreign)
6:25am
POS AM
iumwm7 w4qxhqeh77d
20 Dec 22
Prospectus update (post-effective amendment)
6:17am
6-K
EX-99.3
1i48 f0wn2ca5
28 Nov 22
Current report (foreign)
6:13am
6-K
84lu2u8khwjzhifzta
28 Nov 22
Current report (foreign)
6:03am
6-K
EX-99.2
lwqg9t 2j
7 Nov 22
Current report (foreign)
6:41am
6-K
EX-99.1
95sgtz1 ygbo5
7 Nov 22
Current report (foreign)
6:41am
F-3
vdye6
31 Aug 22
Shelf registration (foreign)
8:35am
6-K
EX-99.2
lqyr8nur3qugmf69d4lp
31 Aug 22
Current report (foreign)
6:36am
6-K
EX-99.1
qrug 6qwr57yl07
19 Aug 22
Jane Bell Joins Mesoblast Board
8:52pm
6-K
EX-99.2
jdj85x9t7sg1jf1wj
20 Jul 22
Current report (foreign)
8:20pm
6-K
EX-99.1
8he8xt8d
14 Jul 22
Rexlemestrocel-l to Be Highlighted at Maxim’s Panel on Late-stage Advancements In Heart Failure Therapeutics and Management
4:00pm
6-K
EX-99.3
4r3hj8220jtlhss8q75e
3 Jun 22
Current report (foreign)
9:26am
6-K
skbjt2dj6 5s8md2pt
2 Jun 22
Current report (foreign)
7:50pm
6-K
EX-99.2
u6y3 v5snht0lntbd
25 Feb 22
Mesoblast Prepares for Resubmission of Biologics License Application
7:46pm
6-K
ba71wzs
25 Feb 22
Provided to the Asx Under Listing Rule 4.2A
12:00am
6-K
EX-99.1
vuj9rkt9
27 Jan 22
Mesoblast to Participate In Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27TH, 2022
9:20pm
F-3ASR
g2v1o
24 Jan 22
Automatic shelf registration (foreign)
6:12am
6-K
EX-99.2
7zseue5pa4soanq 31
19 Jan 22
36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech Showcase
12:00am
6-K
EX-99.1
6a16wiu9
17 Dec 21
Fda’s Otat In Agreement with 12-MONTH Reduction In Pain As Primary Endpoint for Chronic Low Back Pain Program
12:00am